Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months..
Osteoporos Int. 25(5), 1633-42.
(2014). Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial..
J Bone Miner Res.
(2019). Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity..
Metabolism. 71, 198-201.
(2017). Subendothelial carotid hematoma after fine-needle aspiration biopsy of a solitary thyroid nodule..
J Ultrasound Med. 27(10), 1517-20.
(2008). Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study..
Metabolism. 141, 155397.
(2022). Denosumab for the treatment of primary pediatric osteoporosis..
Osteoporos Int.
(2021).
(2017). Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature..
Metabolism. 62(10), 1350-6.
(2013).
(2023). Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study..
Endocrine. 81(3), 573-578.
(2023). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2018). Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial..
Int J Clin Pract. 66(4), 378-83.
(2012). Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans..
Metabolism. 65(10), 1459-65.
(2016). No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial..
Clin Endocrinol (Oxf). 70(4), 522-6.
(2009). Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab..
Ther Clin Risk Manag. 8, 295-306.
(2012). Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis..
Med Hypotheses. 77(1), 109-11.
(2011).
(2021). The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis..
Clin Endocrinol (Oxf). 72(6), 752-7.
(2010). Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society..
Bone. 127, 401-418.
(2019). Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?.
Metabolism. 93, 100-102.
(2019). The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis..
Bone. 158, 116354.
(2022). Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial..
Horm Metab Res. 40(4), 281-5.
(2008). Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview..
Hormones (Athens). 18(1), 65-70.
(2019). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2018).